Entries by Steve

Safe-t Group LTD. – American Depositary Share (NASDAQ:SFET)’s Trend Up, Especially After Decreased Shorts

The stock of Safe-t Group LTD. – American Depositary Share (NASDAQ:SFET) registered a decrease of 42.72% in short interest. SFET’s total short interest was 5,900 shares in July as published by FINRA. Its down 42.72% from 10,300 shares, reported previously. With 61,800 shares average volume, it will take short sellers 0 days to cover their […]

Hidradenitis Suppurativa Treatment Market Size, Industry Status and Growth opportunities for Leading Players| GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer

Los Angeles, United State, July 19, 2019, – The latest report published by QY Research presents a thorough analysis of the global Hidradenitis Suppurativa Treatment market. The research report evaluates the ever-changing market dynamics that are expected to impact the trajectory of the overall market. Analysts studied the historical achievements of the market and compared it […]

Inflarx pushes past the red flags to claim a win

Anyone with more than a fleeting experience of biotech investment should be familiar with the practice of post-hoc data dredging of a failed clinical trial to find hints of activity. Inflarx’s claim yesterday that its clearly negative study of IFX-1 in hidradenitis suppurativa did, after all, show robust efficacy is a particularly egregious example of […]

06-2019-InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa

IFX-1 treatment in high dose group resulted in multiple efficacy signals supporting further development of IFX-1 in HS  IFX-1 suppressed C5a levels dose dependently and exhibited a favorable safety profile with low anti-drug antibody rates  Open-label extension study is ongoing, InflaRx plans end of Phase II regulatory discussions after completion of SHINE trial  Conference call […]

ChemoCentryx, Inc. (CCXI) EPS Estimated At $-0.21; Erytech Pharma S.A. – American Depositary Shares (ERYP) Shorts Decreased By 47.27%

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.21 EPS on August, 8.They anticipate $0.07 EPS change or 50.00% from last quarter’s $-0.14 EPS. After having $-0.23 EPS previously, ChemoCentryx, Inc.’s analysts see -8.70% EPS growth. The stock increased 1.97% or $0.16 during the last trading session, reaching $8.27. About 195,998 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) […]

After-Hours Movers 07/18 (RRGB) (SKX) (CRWD) Higher; (MVIS) (ISRG) (more…)

FREE Breaking News Alerts from StreetInsider.com! StreetInsider.com Top Tickers, 7/18/2019 July 18, 2019 5:40 PM EDT Tweet Send to a Friend Today’s After-Hours MoversMicroVision, Inc. (NASDAQ: MVIS) 29% LOWER; Revenue for the second quarter of 2019 was $1.2 million, compared to … This is a premium only article. To continue reading this article and more […]

G2 Investment Partners Management Lowered By $1.09 Million Its Coherent (COHR) Holding; Xbiotech (XBIT) Sellers Increased By 13.94% Their Shorts

Xbiotech Inc (NASDAQ:XBIT) had an increase of 13.94% in short interest. XBIT’s SI was 1.25 million shares in July as released by FINRA. Its up 13.94% from 1.10 million shares previously. With 293,500 avg volume, 4 days are for Xbiotech Inc (NASDAQ:XBIT)’s short sellers to cover XBIT’s short positions. The SI to Xbiotech Inc’s float […]